LIFE News and Press, aTyr Pharma Inc. From 01/25/21

Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in...

Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for two tRNA synthetases and further validates company’s biology platform. ...

aTyr Pharma's ([[LIFE]] +1.5%) partner Kyorin Pharmaceutical has completed the last subject visit in its Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan). The event triggered milestone payment to aTyr.The Phase 1 trial, will evalua...

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly...

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Offi...

Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's Phase 2 trial.Cyclo ...

ATyr Pharma (LIFE) has announced topline results from its Phase 2 trial evaluating its its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation. The trial met its primary endpoint of safety, dem...

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients receiving 3.0 mg/kg dose of ATYR1923 achieved recovery in less than a week. ...

aTyr Pharma (LIFE) has completed enrollment of 36 patients in its Phase 1b/2a trial of ATYR1923, with pulmonary sarcoidosis, a form of interstitial lung disease ((ILD)). Results expected in Q3 of 2021. The study is evaluating safety, tolerability, immunogenicity and pharmacokinetic profi...

SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has completed the target enrollment in its Phase 1b/2a clinic...